Journey Medical Corp (NASDAQ: DERM) is a pharmaceutical company focused on dermatology that acquires, licenses, and commercializes prescription skin care products. Revenue comes from product sales through a field sales force, supported by licenses from third parties including Dr. Reddy's Laboratories and Maruho Co., Ltd. The company markets prescription dermatology products including Accutane (isotretinoin, launched Q2 2021), Luxamend (a prescription wound care medical device), and an anti-itch product indicated for pruritus and scabies that was planned for launch in the first half of 2026. Journey does not maintain retirement, pension, or profit-sharing plans and has never paid a cash dividend as of the 10-K filed March 26, 2026. The company carries a term loan with SWK Funding LLC (credit agreement dated December 27, 2023) and an accumulated deficit on its balance sheet as of December 31, 2025. Common stock trades on the Nasdaq Capital Market under the symbol DERM, where it began trading on November 12, 2021.

Revenue model

Product sales of prescription dermatology products through a direct field sales force; licensing and collaboration arrangements with partners including Dr. Reddy's Laboratories and Maruho Co., Ltd. No disclosed subscription or royalty income detail in the filing excerpts.

Products and services

Accutane (isotretinoin, marketed since Q2 2021); Luxamend (prescription wound care medical device, water-based wound cream); an anti-itch prescription product indicated for pruritus, scabies, and related conditions, planned for launch in first half of 2026 via field sales force.

Customers and end markets

Prescription dermatology market; end customers are patients treated by dermatologists and prescribing physicians. Products distributed through wholesalers. No specific customer concentration percentages disclosed in the filing excerpts.

Value-chain role

Specialty pharmaceutical commercialization company. Acquires or in-licenses products rather than conducting primary discovery. Relies on third-party contract research organizations for clinical development and third parties for warehousing, distribution, and cash collection. Holds licenses from Dr. Reddy's Laboratories and Maruho Co., Ltd.

Geographic exposure

Primary operations in the United States; listed on Nasdaq Capital Market. No specific international revenue breakdown disclosed in the filing excerpts.

Source: SEC 10-K, filed 2026-03-26

Industry: Pharmaceutical Preparations Peers: 9 METERS BIOPHARMA, INC. DMK PHARMACEUTICALS Corp Akari Therapeutics PLC NRX Pharmaceuticals Inc Opus Genetics Inc Eton Pharmaceuticals Inc Johnson & Johnson OPIANT PHARMACEUTICALS, INC.